Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
418 Leser
Artikel bewerten:
(1)

Eagle Genomics Expands Into US With Residency at JLABS in Manhattan

A panel discussion with industry leaders on the future of microbiome R&D headlined a celebratory launch event in New York City

NEW YORK, July 30, 2019 /PRNewswire/ -- Eagle Genomics, the life sciences knowledge discovery platform company, is excited to announce that its new office at JLABS in Manhattan, New York City, opened its doors on Thursday, July 25. As part of the New York Genome Center community the new residency space at JLABS places Eagle Genomics at the heart of genomics research in New York, alongside other companies with a focus on life sciences and data-driven innovation.

Eagle Genomics logo (PRNewsfoto/Eagle Genomics)

Eagle Genomics' e[automateddatascientist] is the platform behind the brains solving the world's life sciences challenges. Enabling rapid improvement of productivity and accelerating time to insight and product delivery, Eagle Genomics' conversational learning software platform has the ability to handle the complexity and scale of genomics and microbiomics data.

With the launch of the Manhattan space, Eagle Genomics solidifies its presence in the US and positions itself at the emerging center of international genomics innovation, where deep tech meets deep science.

"We are delighted to be expanding our presence in the US and to be joining the innovative community at JLABS," said Anthony Finbow, Chief Executive Officer at Eagle Genomics. "Having a home at the heart of genomics research in New York, close to many of our customers, will provide an even deeper understanding of the challenges they face and enable the platform to be deployed to assist in pushing the boundaries of scientific research and addressing the grand challenges of our age."

At the July 25 event, industry leaders participated in a panel discussion to answer the question 'Will the microbiome revolution happen?'. Panellists included: leading microbiome researcher, Dirk Gevers, Global Head of Microbiome Solutions, World Without Disease Accelerator at Janssen; Sam Samaras, Global Vice President Science & Technology, Beauty and Personal Care R&D at Unilever; Rob Genieser, Managing Partner of venture capital firm ETF Partners; and David Houlding, Principal Healthcare Lead, Industry Experiences, Cloud + AI at Microsoft.

Eagle Genomics' platform has already led to product innovation globally. Utilizing Eagle Genomics' software platform, Unilever, a leader in the consumer goods industry, was able to make the first microbiome product claim with the creation of its Zendium toothpaste in 2017.

Using the e[automateddatascientist] Unilever was able to assess the effects and ability of enzymes and proteins to boost salivary defences and produced a toothpaste that, when used by consumers, showed a demonstrable shift in plaque oral microbiome ecology.

The Manhattan base joins Eagle Genomics' current spaces which include the world-leading Wellcome Genome Campus in Cambridge, UK, as well as major AI innovation centers at Microsoft AI's Station F in Paris and London's Knowledge Quarter.

To find out more about how Eagle Genomics is revolutionizing product development and delivery with its conversational learning platform, visit our website.

About Eagle Genomics

Eagle Genomics' award-winning AI augmented knowledge discovery platform,
the e[automateddatascientist], is revolutionizing how scientists conduct life sciences research and is bridging the gap between data and insight in a rapid, systematic and traceable way. It puts data science at the fingertips of biologists to drastically reduce time and cost of research, enabling customers to achieve radical productivity improvements and true data-driven discovery.

Find out more at www.eaglegenomics.com

About JLABS

JLABS @ NYC is a 30,000 square-foot life science incubator. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a "no strings attached" model, Johnson & Johnson Innovation does not take an equity stake in the companies occupying JLABS and the companies are free to develop products -either on their own, or by initiating a separate external partnership with Johnson & Johnson Innovation or any other company.

Logo - https://mma.prnewswire.com/media/768502/Eagle_Genomics_Logo.jpg
Photo - https://mma.prnewswire.com/media/954122/Eagle_Genomics_Launch_Panel.jpg

Press Contact:

Georgia Hingston, Content Marketing Executive at Eagle Genomics: georgia.hingston@eaglegenomics.com Tel: +44 (0)1223 786 027

Industry experts from Unilever, Janssen, Microsoft and ETF Partners discuss

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2019 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.